Compare ACP & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACP | ZVRA |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 653.2M |
| IPO Year | N/A | 2015 |
| Metric | ACP | ZVRA |
|---|---|---|
| Price | $5.33 | $10.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 481.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $17.44 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $4.99 | $7.16 |
| 52 Week High | $5.99 | $13.16 |
| Indicator | ACP | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 48.41 |
| Support Level | $5.24 | $8.30 |
| Resistance Level | $5.48 | $11.07 |
| Average True Range (ATR) | 0.07 | 0.64 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 35.00 | 25.76 |
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.